Skip to main content
HINOVA PHARMACEUTICALS INC. logo

HINOVA PHARMACEUTICALS INC. — Investor Relations & Filings

Ticker · 688302 ISIN · CNE1000059F5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2024-04-12 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688302

About HINOVA PHARMACEUTICALS INC.

https://www.hinovapharma.com/

Hinova Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of cancers and metabolic diseases. The company leverages its core technology platforms, including targeted protein degradation (PROTAC) and deuterium-based drug discovery, to develop a diverse pipeline of small molecule therapeutics. Its lead candidate, HC-1119 (deuterenzalutamide), is a next-generation androgen receptor antagonist currently in late-stage clinical development for metastatic castration-resistant prostate cancer. Other key programs include HP518, an orally bioavailable PROTAC degrader targeting the androgen receptor, and HP501, a selective URAT1 inhibitor designed for the treatment of hyperuricemia and gout. Hinova aims to address significant unmet medical needs through the development of high-quality, differentiated therapies for global markets.

Recent filings

Filing Released Lang Actions
独立董事独立性自查情况表-彭永臣
Regulatory Filings Classification · 95% confidence The document is a special report on the independence of the company's independent directors, referencing regulatory requirements and self-assessment of independence. It is not an annual report, audit report, or financial statement. It is a regulatory compliance report related to governance but does not detail governance structure or compensation. It is a standalone regulatory filing about director independence, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories and is a compliance disclosure.
2024-04-12 Chinese
2023年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2023 Annual Report Summary" of the company 海创药业股份有限公司. It contains detailed financial data for the year 2023, including total assets, net profit, revenue, and quarterly financial data. It also includes extensive management discussion and analysis about the company's business, industry, products, and future outlook. The document is comprehensive and covers the full fiscal year, consistent with an official annual report. There is no indication that this is merely an announcement or a certification. The length of the document (12,876 characters) and the detailed financial and operational information confirm it is the actual Annual Report. Therefore, the correct classification is Annual Report (10-K). FY 2023
2024-04-12 Chinese
关于使用部分闲置自有资金进行现金管理的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about the use of idle funds for cash management, detailing the board's approval, purpose, risk control measures, and opinions from independent directors and the supervisory board. It does not contain financial statements or detailed financial performance data. It is a regulatory announcement about a financial decision rather than a report or detailed financial disclosure. The document length is short (2135 characters), and it is an announcement of a corporate action related to cash management. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-04-12 Chinese
2023年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled '2023 年度监事会工作报告' which translates to '2023 Supervisory Board Work Report'. It details the supervisory board's activities, oversight of company operations, financial status, internal controls, related party transactions, and fundraising management for the year 2023. The content is a formal report from the supervisory board to shareholders and stakeholders about their oversight work during the fiscal year. It is not an announcement or a brief summary but a detailed report on governance and supervisory activities. This fits the category of a Management Report (MDA), which includes management's detailed explanation of financial results, business trends, and outlook. The document is not an Annual Report (10-K) or Audit Report (AR) as it focuses on supervisory board activities rather than full financial statements or audit opinions. It is also not a Regulatory Filing (RNS) or Report Publication Announcement (RPA) because it contains substantive content rather than just an announcement or certification. Therefore, the best classification is Management Reports (MDA).
2024-04-12 Chinese
2023年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2023年度募集资金存放与实际使用情况的专项报告" which translates to "2023 Annual Special Report on the Deposit and Actual Use of Raised Funds." It details the company's fundraising activities, including the amount raised, usage of funds, management of funds, and investment projects funded by the raised capital. It references regulatory guidelines related to fundraising management and includes detailed financial figures about the raised funds and their usage. The document is a specialized report focused on the management and use of capital raised by the company, not a general annual report or earnings release. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length is sufficient and contains substantive financial data related to fundraising usage, not merely an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2024-04-12 Chinese
德勤华永会计师事务所(特殊普通合伙)出具的《海创药业股份有限公司2023年度内部控制审计报告》
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report' dated December 31, 2023. It is issued by Deloitte Huayong CPA firm, a registered accounting firm, and contains an audit opinion on the effectiveness of the company's internal control over financial reporting. The content includes responsibilities of the company and auditors, inherent limitations of internal control, and the auditor's opinion on the internal control effectiveness. This is a standalone audit report focused on internal control, not a full annual report or interim financial report. It matches the definition of an Audit Report / Information (AR) filing, which includes standalone audit reports and applied accounting principles. The document length is sufficient and contains substantive audit content, not merely an announcement or certification. Therefore, the correct classification is AR with high confidence. FY 2023
2024-04-12 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.